TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 5, 4:09 PM ET

Daniell Richard 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Daniell Richard
EVP, Europe Commercial
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1][F2]
    2026-03-03+62,250110,634 total
  • Sale

    Ordinary Shares

    [F1][F3][F4][F5]
    2026-03-03$32.36/sh62,250$2,014,40448,384 total
  • Exercise/Conversion

    Ordinary Shares

    [F1][F2]
    2026-03-03+141,478189,862 total
  • Sale

    Ordinary Shares

    [F1][F3][F4][F5]
    2026-03-03$32.36/sh66,735$2,159,538123,127 total
  • Exercise/Conversion

    Restricted Share Units

    [F2][F6][F1]
    2026-03-0362,25062,253 total
    Ordinary Shares (62,250 underlying)
  • Exercise/Conversion

    Restricted Share Units

    [F2][F7][F1]
    2026-03-03141,4780 total
    Ordinary Shares (141,478 underlying)
Footnotes (7)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
  • [F4]Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 4, 2027.
  • [F7]Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell|2026-03-05

Documents

1 file
  • 4
    ownership.xmlPrimary

    4